Cerevel Therapeutics Holdings Overview

Cerevel Therapeutics Holdings Research & Development

Research & Development expenses for CERE.

Quarterly R&D Expenses

$106.42M

↑ 36.13% YoY

As of Mar 31, 2024

Annual R&D Expenses (TTM)

$362.88M

↑ 19.6% YoY

Trailing 12 months ending Mar 31, 2024

Average R&D Expenses (Comparison Companies)

Research & Development History

Research & Development Comparison

Annual Research & Development Growth Rate (%)

Annual Research & Development Growth (Absolute)

Jump to metric

Total Revenue Cost of Revenue Gross Profit Research & Development Selling, General & Admin Operating Income Other Income Expense Net EBIT Income Tax Net Income Profit Margin